Subsequently, we used transcriptome sequencing and various molecular biology techniques to elucidate the mechanism by which PLCG2 accelerated the malignant progression of CRC through activation of the Akt-mTOR pathway both in vivo and in vitro. The gene discussed is MTOR; the disease is colorectal carcinoma.